GlassScriptPhysician profile
Brian C Pien
NPI 1457436941
$19,066.69
in general payments reported to CMS, 2019-2025
26 companies · $3,263 in 2025
The $3,263 reported for 2025 was more than what 89% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,904 · 2020: $2,258 · 2021: $3,147 · 2022: $2,986 · 2023: $2,654 · 2024: $2,855 · 2025: $3,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,770 · Education: $2.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,769.72 |
| Education | $2.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,318.61 | 2019-2025 | Biktarvy, Veklury, Epclusa |
| Insmed, INC. | $4,224.68 | 2019-2025 | Arikayce, Brinsupri |
| Viiv Healthcare Company | $2,480.75 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $1,929.22 | 2021-2025 | |
| Cumberland Pharmaceuticals, INC. | $1,346.73 | 2019-2025 | Vibativ |
| Merck Sharp & Dohme LLC | $1,072.36 | 2019-2025 | Capvaxive, Pifeltro, Delstrigo |
| Janssen Biotech, INC. | $826.28 | 2019-2023 | Symtuza, Prezcobix |
| Melinta Therapeutics, LLC | $644.42 | 2019-2025 | Kimyrsa, Rezzayo, Vabomere |
| Shionogi INC | $338.27 | 2024-2025 | Fetroja |
| Allergan, INC. | $319.23 | 2019-2020 | |
| Emd Serono, INC. | $239.74 | 2019-2025 | Serostim |
| Astellas Pharma US INC | $227.99 | 2019-2020 | |
| Smith+Nephew, INC. | $198.52 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $154.56 | 2023-2025 | Rebyota |
| Novo Nordisk INC | $152.46 | 2019-2025 | Ozempic |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $150.46 | 2024-2025 | Vowst |
| Vyera Pharmaceuticals, LLC | $107.01 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $85.73 | 2019-2022 | |
| Pfizer INC. | $70.09 | 2023-2025 | |
| Lilly USA, LLC | $43.75 | 2023-2024 | Zepbound, Mounjaro |
| Tactile Systems Technology INC | $37.49 | 2020 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Esperion Therapeutics, INC. | $24.05 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $17.33 | 2020 | |
| Amarin Pharma, INC. | $17.32 | 2019 | |
| Napo Pharmaceuticals INC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Pien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.